Antibody levels predictive of Moderna’s vaccine efficacy -study

Antibody levels are a good predictor for how effective Moderna Inc’s COVID-19 vaccine is, according to a new study released on Tuesday, a finding which could help speed up future clinical trials for vaccines against the disease. Regulators currently rely on large placebo-controlled studies to determine if a vaccine works, but the study, conducted by scientists from the Fred Hutchinson Cancer Research Center, the National Institute of Allergy and Infectious Diseases, Moderna and elsewhere, showed that measuring the antibody levels in vaccine recipients could also determine effectiveness. The study, which has not yet been peer-reviewed, found that the Moderna vaccine was more effective in vaccine recipients with high levels of antibodies.


Please enter your comment!
Please enter your name here